La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Hofseth BioCare Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Jon Odegard

Directeur général

NOK 2.8m

Rémunération totale

Pourcentage du salaire du PDG	58.6%
Durée du mandat du directeur général	2.1yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	3.6yrs
Durée moyenne du mandat des membres du conseil d'administration	2.4yrs

Mises à jour récentes de la gestion

Recent updates

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20

Analyse de la rémunération des PDG

Comment la rémunération de Jon Odegard a-t-elle évolué par rapport aux bénéfices de Hofseth BioCare?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-NOK 121m
Mar 31 2024	n/a	n/a	-NOK 98m
Dec 31 2023	NOK 3m	NOK 2m	-NOK 107m
Sep 30 2023	n/a	n/a	-NOK 93m
Jun 30 2023	n/a	n/a	-NOK 105m
Mar 31 2023	n/a	n/a	-NOK 140m
Dec 31 2022	n/a	n/a	-NOK 137m
Sep 30 2022	n/a	n/a	-NOK 136m
Jun 30 2022	n/a	n/a	-NOK 139m
Mar 31 2022	n/a	n/a	-NOK 135m
Dec 31 2021	n/a	n/a	-NOK 126m
Sep 30 2021	n/a	n/a	-NOK 120m
Jun 30 2021	n/a	n/a	-NOK 115m
Mar 31 2021	n/a	n/a	-NOK 111m
Dec 31 2020	NOK 2m	NOK 695k	-NOK 102m
Sep 30 2020	n/a	n/a	-NOK 104m
Jun 30 2020	n/a	n/a	-NOK 90m
Mar 31 2020	n/a	n/a	-NOK 86m
Dec 31 2019	NOK 2m	NOK 660k	-NOK 89m
Sep 30 2019	n/a	n/a	-NOK 79m
Jun 30 2019	n/a	n/a	-NOK 81m
Mar 31 2019	n/a	n/a	-NOK 83m
Dec 31 2018	NOK 2m	NOK 702k	-NOK 85m
Sep 30 2018	n/a	n/a	-NOK 74m
Jun 30 2018	n/a	n/a	-NOK 66m
Mar 31 2018	n/a	n/a	-NOK 66m
Dec 31 2017	NOK 2m	NOK 2m	-NOK 16m

Rémunération vs marché: La rémunération totale de Jon ($USD 269.52K ) est dans la moyenne des entreprises de taille similaire sur le marché Norwegian ($USD 306.22K ).

Rémunération et revenus: La rémunération de Jon a augmenté alors que l'entreprise n'est pas rentable.

PDG

Jon Odegard

2.1yrs

Titularisation

NOK 2,841,000

Compensation

Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Jon Odegard	Chief Executive Officer	2.1yrs	NOK 2.84m	pas de données
Christel Kanli	CFO & COO	1.5yrs	NOK 1.45m	0.018% NOK 127.6k
Bomi Framroze	Chief Scientific Officer	14.7yrs	NOK 9.44m	1.26% NOK 9.0m
James Berger	Chief Commercial Officer	3.6yrs	NOK 501.00k	pas de données
Angelika Florvaag	Chief Quality Officer	3.6yrs	NOK 1.26m	pas de données

3.6yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de HBC est considérée comme expérimentée (ancienneté moyenne 3.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Crawford Linden Currie	Director	2.7yrs	NOK 96.00k	0.18% NOK 1.3m
Roger Hofseth	Director	2.1yrs	NOK 96.00k	16.91% NOK 119.9m
Maria Bech	Director	less than a year	pas de données	pas de données
Amy Novogratz	Independent Director	2.8yrs	pas de données	pas de données
Christoph Baldegger	Independent Director	9.7yrs	NOK 116.00k	0.19% NOK 1.4m
Linda Hoff	Chair of the Board	less than a year	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de HBC ne sont pas considérés comme expérimentés (ancienneté moyenne 2.3 ans), ce qui suggère un nouveau conseil d'administration.

Hofseth BioCare Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Less than half of directors are independent

Hofseth BioCare ASA Announces Board Changes

CFO & COO recently bought kr200k worth of stock

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Hofseth BioCare ASA Announces Executive Changes

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.015 profit in 2Q 2023)

Less than half of directors are independent

First quarter 2024 earnings released: kr0.07 loss per share (vs kr0.096 loss in 1Q 2023)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

New minor risk - Share price stability

Hofseth BioCare ASA Announces Board Changes

New major risk - Financial position

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

CFO & COO recently bought kr200k worth of stock

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Executive Officer recently bought kr367k worth of stock

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Chief Commercial Officer recently bought kr200k worth of stock

Chief Executive Officer recently bought kr361k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Independent Director recently bought kr385k worth of stock

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

New 90-day high: kr9.80

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: kr7.98

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - kr8.16

First half earnings released

Hofseth BioCare ASA (OB:HBC) acquired a 34% stake in Atlantic Delights Ltd. for $0.7 million.